The prevalence of germline BRCA1/2 mutations in Chinese breast cancer patients varies among the previous studies (1.8%~18.2%)[3–5], largely due to differences in patient selection criteria, sensitivity and specificity of detection assays, and mutation calling methods. The gene discussed is BRCA1; the disease is breast cancer.